Insilico Medicine (HKG: 3696) announced that ISM4808, an AI-driven PHD inhibitor for chronic kidney disease (CKD)-related anemia, has achieved its first development milestone. Licensee TaiGen Biotechnology (TaiGen*-KY, 4157) has successfully completed enrollment and dosing of the first subject in the Phase I clinical trial, triggering milestone payments under the December 2025 licensing agreement.
Contents
Regulatory & Clinical Milestone
| Item | Detail |
|---|---|
| Drug | ISM4808 (oral HIF-PHD inhibitor) |
| Indication | Chronic kidney disease (CKD)-related anemia |
| Milestone | First subject enrolled and dosed in Phase I |
| Licensee | TaiGen Biotechnology (TaiGen*-KY, 4157) |
| Territory | Greater China (mainland China, Hong Kong, Macau, Taiwan) |
| Achievement Date | March 2026 |
| Next Steps | Phase I safety/tolerability data readout expected H2 2026 |
Drug Profile & Mechanism
| Attribute | ISM4808 Profile |
|---|---|
| Discovery Platform | Insilico Medicine’s Chemistry42 (generative AI chemistry) |
| Target | Hypoxia-inducible factor prolyl hydroxylase (HIF-PHD) |
| Mechanism | Stimulates endogenous erythropoietin (EPO) production; improves iron utilization |
| Route | Oral administration |
| Differentiation | Best-in-class potential vs. existing IV erythropoiesis-stimulating agents (ESAs) |
Clinical Advantages:
- Improved iron use efficiency vs. traditional ESAs
- Avoidance of intravenous injections (patient convenience)
- Favorable safety profile (reduced cardiovascular risk vs. ESAs)
- Potential to overcome hyporesponsiveness seen in current therapies
Financial Terms
| Component | Structure |
|---|---|
| Upfront Payment | Received by Insilico (December 2025) |
| Milestone Payments | Development and sales-based triggers (first Phase I milestone now achieved) |
| Royalties | Tiered royalties on net sales |
| Total Deal Value | Tens of millions of US dollars |
| Rights Granted | Exclusive development, commercialization, and sublicensing rights in Greater China |
Strategic Context
| Factor | Implication |
|---|---|
| AI Validation | ISM4808 progression validates Insilico’s Chemistry42 platform for de novo drug design |
| Market Opportunity | China CKD anemia market estimated $2+ billion; oral HIF-PHD inhibitors displacing injectable ESAs |
| Competitive Landscape | Roxadustat (FibroGen/AstraZeneca) first-to-market; ISM4808 targets improved safety/efficacy profile |
| Partnership Model | Asset-light strategy: Insilico retains ex-China rights; TaiGen funds regional development |
Pipeline & Platform Outlook
- Insilico Portfolio: 30+ AI-discovered programs across fibrosis, oncology, immunology; ISM4808 first CKD asset to reach clinic
- Platform Expansion: Chemistry42 now deployed for multiple pharma partnerships; milestone achievement demonstrates commercial viability
- TaiGen Strategy: Builds anemia franchise alongside existing portfolio; Greater China commercial infrastructure leveraged
Forward‑Looking Statements
This brief contains forward‑looking statements regarding clinical development timelines, milestone achievements, and commercial potential for ISM4808. Actual results may differ due to trial outcomes, regulatory requirements, and competitive dynamics in the CKD anemia market.-Fineline Info & Tech
